Phase 1b/2a Study Combining LY2157299 With Standard Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma.
Phase of Trial: Phase I/II
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Galunisertib (Primary) ; Temozolomide
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
- Focus Adverse reactions; Biomarker; Proof of concept; Therapeutic Use
- Sponsors Eli Lilly
- 07 Jun 2017 Biomarkers information updated
- 15 Feb 2017 Status changed from active, no longer recruiting to completed.
- 03 Feb 2017 This trial was completed in Germany (End date: 23 Nov 2016), according to European Clinical Trials Database.